U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C33H32FO6.Na
Molecular Weight 566.5918
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETALOCIB SODIUM

SMILES

[Na+].CCCC1=C(OC2=C(C=CC=C2)C([O-])=O)C=CC=C1OCCCOC3=C(CC)C=C(C(O)=C3)C4=CC=C(F)C=C4

InChI

InChIKey=GKDIMGQSBSDJNC-UHFFFAOYSA-M
InChI=1S/C33H33FO6.Na/c1-3-9-25-29(12-7-13-30(25)40-31-11-6-5-10-26(31)33(36)37)38-18-8-19-39-32-21-28(35)27(20-22(32)4-2)23-14-16-24(34)17-15-23;/h5-7,10-17,20-21,35H,3-4,8-9,18-19H2,1-2H3,(H,36,37);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C33H32FO6
Molecular Weight 543.602
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Etalocib (LY-293111 or VML 295) is a potent and orally active leukotriene B4 receptor antagonist of the biphenylphenol class. It efficiently blocks neutrophil activation and subsequent inflammation. Additionally, it exerts antineoplastic properties through induction of cell cycle arrest and apoptosis in tumor cells. Etalocib was being developed for the treatment of inflammatory diseases and solid tumors.

Approval Year

PubMed

PubMed

TitleDatePubMed
Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies.
1999 Jan
Effects of leukotriene B4 receptor antagonist, LY293111Na, on antigen-induced bronchial hyperresponsiveness and leukocyte infiltration in sensitized guinea pigs.
2001 Mar
Preclinical characterization of 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic acid metabolism: in vitro species comparison and in vivo disposition in rats.
2003 Nov
The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer.
2008
5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis.
2010
Patents

Patents

Substance Class Chemical
Created
by admin
on Fri Dec 15 15:34:37 GMT 2023
Edited
by admin
on Fri Dec 15 15:34:37 GMT 2023
Record UNII
993NUX18GO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETALOCIB SODIUM
Common Name English
BENZOIC ACID, 2-(3-(3-((5-ETHYL-4'-FLUORO-2-HYDROXY(1,1'-BIPHENYL)-4-YL)OXY)PROPOXY)-2-PROPYLPHENOXY)-, MONOSODIUM SALT
Common Name English
LY-293111 SODIUM
Code English
VML-295
Code English
Code System Code Type Description
FDA UNII
993NUX18GO
Created by admin on Fri Dec 15 15:34:38 GMT 2023 , Edited by admin on Fri Dec 15 15:34:38 GMT 2023
PRIMARY
CAS
152608-41-8
Created by admin on Fri Dec 15 15:34:38 GMT 2023 , Edited by admin on Fri Dec 15 15:34:38 GMT 2023
PRIMARY
PUBCHEM
23663993
Created by admin on Fri Dec 15 15:34:38 GMT 2023 , Edited by admin on Fri Dec 15 15:34:38 GMT 2023
PRIMARY
EPA CompTox
DTXSID40934557
Created by admin on Fri Dec 15 15:34:38 GMT 2023 , Edited by admin on Fri Dec 15 15:34:38 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY